Related Experiment Video
Updated: Jun 8, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
[Immunotherapy and Alzheimer's disease]
1Department of Psychiatry, Juntendo University Faculty of Medicine, Tokyo, Japan. heii@juntendo.ac.jp
Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology
|September 23, 2010
Summary
Alzheimer's disease (AD) treatments are advancing with immunotherapy. New approaches target specific Abeta protein parts, moving beyond earlier methods that caused severe side effects like encephalitis.
Area of Science:
- Neuroscience
- Immunology
- Biomedical Research
Context:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options.
- Immunotherapy, targeting amyloid-beta (Abeta) protein, is a leading therapeutic strategy for AD.
- Previous active immunotherapy attempts faced challenges due to severe side effects like encephalitis.
Purpose:
- To review the current landscape of Alzheimer's disease treatment strategies.
- To discuss the advancements and challenges in Abeta-based immunotherapy for AD.
- To explore future directions in developing effective AD therapies.
Summary:
- Biological studies have advanced AD treatment strategies, with immunotherapy being a key focus.
- Early active immunotherapy using full-length Abeta protein was halted due to encephalitis.
- Revised immunotherapies, including humanized monoclonal antiserum targeting specific Abeta fragments, are now in clinical trials for AD.
Impact:
- This review provides insights into the evolving field of AD therapeutics.
- Understanding the progress in immunotherapy can guide future research and clinical development for AD.
- The findings highlight the potential for improved treatment outcomes for individuals with Alzheimer's disease.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:19Psychoneuroimmunology: Diabetes and Cancer
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...